Cashu
Syndax Pharmaceuticals Faces Mixed Analyst Sentiment Amidst Biotech Sector Challenges
3 days ago
Stocks
Health Care
sndx
Syndax Pharmaceuticals
NASDAQ: SNDX
-0.67 (-3.93%)
16.37
USD
At close at Sep 08, 18:41 UTC
Overview
Loading chart...
Key Stats
Market Cap
1.47B
Dividend Yield
0.00%
P/E Ratio
-4.38
EPS
-3.72
Revenue
23.68M
Avg. Volume
1.99M
About
What does SNDX do?
Syndax Pharmaceuticals, based in Waltham, Massachusetts, develops cancer therapies and went public on March 3, 2016. Key products include revumenib for leukemia and axatilimab for chronic graft-versus-host disease.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.